Business
Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs
SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), for PPD to oversee the company's clinical studies investigating the Hemopurifier, Aethlon's therapeutic blood filtration system, for infectious disease indications.\nPursuant to the agreement, PPD will manage Aethlon's ongoing study of the Hemopurifier for patients who are critically ill with COVID-19 (NCT04595903). PPD and Aethlon also can agree to include additional studies under their agreement.\n\"Aethlon is committed to progressing the clinical development of the Hemopurifier,\" said Charles J. Fisher, M.D., Chief Executive Officer of Aethlon Medical. \"PPD is a world class organization with significant experience operating clinical studies. Aethlon plans to move quickly to leverage this experience to advance our studies of the Hemopurifier in COVID-19 patients.\"\nAbout Aethlon and the Hemopurifier®\nAethlon Medical is a biotechnology company developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer, as its lead technology. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.\nThe Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, the FDA approved a single site, open-label Early Feasibility Study (EFS) to evaluate the Hemopurifier for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The ...